Sonia Chilundo
Research Subjects
Research Interests
Sonia Chilundo has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Aleny Couto
Ministry of Health (MISAU), Mozambique
1 shared publication- Aleny Couto
National HIV and STI Control Program, Ministry of Health, Salvador Allende 1008, Maputo 1101, Mozambique
1 shared publication Alexandre Nguimfack
Division of Global HIV & TB (DGHT), U.S. Centers for Disease Control and Prevention (CDC), Mozambique
1 shared publication- Amancio Nhangave
Operational Research Unit, Gaza Provincial Health Directorate, Rua do Hospital Provincial, 33 Bairro 13, Cidade de Xai-Xai 1200, Mozambique
1 shared publication - Ana Muteerwa
Division of Global HIV & TB, U.S. Centers for Diseases Control and Prevention, Avenida Marginal 5467, Maputo 1101, Mozambique
1 shared publication António Langa
U.S. Department of Defense (DOD), Mozambique
1 shared publication
Latest Publications
- Open Access
HIV Drug Resistance Profile in Clients Experiencing Treatment Failure After the Transition to a Dolutegravir-Based First-Line Antiretroviral Treatment Regimen in Mozambique
Real-world data on HIV drug resistance (HIVDR) after transitioning to tenofovir disoproxil fumarate/lamivudine/dolutegravir (TLD) are limited. We assessed HIVDR rates and patterns in clients with virological failure (VF) after switching from an NNRTI-based regimen to TLD. A cross-sectional study was conducted in Gaza, Mozambique (August 2021–February 2022), including adults on first-line ART for ≥12 months who transitioned to TLD and had unsuppressed viral load (VL) ≥ 1000 copies/mL six months post-transition. After three adherence counseling sessions, participants with VF underwent genotyping for drug resistance mutations (DRMs) using the Stanford HIVdb Program. Of 717 participants (median age 39.2 years, 70.7% female), 217 (30.2%) had VF, 193 (88.9%) underwent genotyping, with 183 (94.8%) successfully genotyped. Intermediate–high dolutegravir (DTG) resistance was found in 19.6% (36/183). Unsuppressed VL before DTG transition was independently associated with VF (aOR: 2.14). Resistance patterns included 33.3% (12/36; 95% CI: 14.6–46.3) to all three TLD drugs, 55.6% (20/36; 95% CI: 39.3–71.9) to DTG and 3TC, and 11% (4/36; 95% CI: 0.8–21.3) to DTG only. Major drug resistance mutations to DTG included G118R (9.3%), R263K (6.6%), and Q148H/R/K (4.4%). This study highlights the need to consider virologic status before transitioning PLHIV to TLD and suggests that adherence counseling may not prevent resistance in those with unknown or prior VF.
Open AccessHIV Drug Resistance Profile in Clients Experiencing Treatment Failure After the Transition to a Dolutegravir-Based First-Line Antiretroviral Treatment Regimen in Mozambique
Real-world data on HIV drug resistance (HIVDR) after transitioning to tenofovir disoproxil fumarate/lamivudine/dolutegravir (TLD) are limited. We assessed HIVDR rates and patterns in clients with virological failure (VF) after switching from an NNRTI-based regimen to TLD. A cross-sectional study was conducted in Gaza, Mozambique (August 2021–February 2022), including adults on first-line ART for ≥12 months who transitioned to TLD and had unsuppressed viral load (VL) ≥ 1000 copies/mL six months post-transition. After three adherence counseling sessions, participants with VF underwent genotyping for drug resistance mutations (DRMs) using the Stanford HIVdb Program. Of 717 participants (median age 39.2 years, 70.7% female), 217 (30.2%) had VF, 193 (88.9%) underwent genotyping, with 183 (94.8%) successfully genotyped. Intermediate–high dolutegravir (DTG) resistance was found in 19.6% (36/183). Unsuppressed VL before DTG transition was independently associated with VF (aOR: 2.14). Resistance patterns included 33.3% (12/36; 95% CI: 14.6–46.3) to all three TLD drugs, 55.6% (20/36; 95% CI: 39.3–71.9) to DTG and 3TC, and 11% (4/36; 95% CI: 0.8–21.3) to DTG only. Major drug resistance mutations to DTG included G118R (9.3%), R263K (6.6%), and Q148H/R/K (4.4%). This study highlights the need to consider virologic status before transitioning PLHIV to TLD and suggests that adherence counseling may not prevent resistance in those with unknown or prior VF.
- Open Access
HIV Antiretroviral Therapy Scale-Up in Mozambique and Estimated Averted HIV Infections and Related Deaths, 2004–2023
Introduction: Mozambique is a HIV high-burden country. In 2004, Mozambique had an estimated HIV prevalence of 15.6% and 1.5 million people living with HIV (PLHIV). During same year the country started antiretroviral therapy (ART) scale-up supported by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR). We describe the ART scale-up and estimate averted HIV infections and HIV-related deaths. Methods: We analyzed PEPFAR Monitoring, Evaluation, and Reporting program data from fiscal year 2004 to 2023. Before October 2018, PLHIV on ART were defined as clients with ≤90 days since last missed visit; in October 2018, this changed to ≤28 days. Viral load suppression (VLS) rate was calculated as PLHIV at PEPFAR-supported sites with VLS (<1,000 viral copies/mL) among those tested in previous 12 months. We used the 2024 United Nations Programme on HIV/AIDS (UNAIDS) Spectrum AIDS Impact Model and Goals Age Structured Model (ASM) to estimate HIV infections and HIV-related deaths averted. Results: By September 2023, 2.1 million PLHIV in Mozambique were receiving PEPFAR-supported ART (1.4 million women [66%]; 1.9 million aged ≥15 years [95%]), a 650-fold increase from 3,226 in March 2004. The VLS rate increased from 62% (78,808/126,212) in 2017 to 94% (1,235,626/1,318,544) in 2023. During 2004–2023, ART scale-up helped avert an estimated 1.6 million HIV infections, including over 350,000 infections among HIV-exposed infants, and 1,070,295 HIV-related deaths. Conclusion: The over 20 years of Mozambique’s scaled up ART effort has greatly expanded effective treatment and averted many new infections and HIV-related deaths. While progress has been impressive, gaps remain toward ending HIV as a public health threat.
Open AccessHIV Antiretroviral Therapy Scale-Up in Mozambique and Estimated Averted HIV Infections and Related Deaths, 2004–2023
Introduction: Mozambique is a HIV high-burden country. In 2004, Mozambique had an estimated HIV prevalence of 15.6% and 1.5 million people living with HIV (PLHIV). During same year the country started antiretroviral therapy (ART) scale-up supported by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR). We describe the ART scale-up and estimate averted HIV infections and HIV-related deaths. Methods: We analyzed PEPFAR Monitoring, Evaluation, and Reporting program data from fiscal year 2004 to 2023. Before October 2018, PLHIV on ART were defined as clients with ≤90 days since last missed visit; in October 2018, this changed to ≤28 days. Viral load suppression (VLS) rate was calculated as PLHIV at PEPFAR-supported sites with VLS (<1,000 viral copies/mL) among those tested in previous 12 months. We used the 2024 United Nations Programme on HIV/AIDS (UNAIDS) Spectrum AIDS Impact Model and Goals Age Structured Model (ASM) to estimate HIV infections and HIV-related deaths averted. Results: By September 2023, 2.1 million PLHIV in Mozambique were receiving PEPFAR-supported ART (1.4 million women [66%]; 1.9 million aged ≥15 years [95%]), a 650-fold increase from 3,226 in March 2004. The VLS rate increased from 62% (78,808/126,212) in 2017 to 94% (1,235,626/1,318,544) in 2023. During 2004–2023, ART scale-up helped avert an estimated 1.6 million HIV infections, including over 350,000 infections among HIV-exposed infants, and 1,070,295 HIV-related deaths. Conclusion: The over 20 years of Mozambique’s scaled up ART effort has greatly expanded effective treatment and averted many new infections and HIV-related deaths. While progress has been impressive, gaps remain toward ending HIV as a public health threat.